The Global Vaccines Market, 2008-2023

Content

• 1 Executive Summary
• 2 Vaccines and Vaccine-Preventable Diseases
  • 2.1 Immunisation and Types of Vaccine
    • 2.1.1 Vaccines: A Healthcare Triumph
    • 2.1.2 The Immune System and Natural Immunity
    • 2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines
    • 2.1.4 Vaccines Work by Creating Artificial Immunity
    • 2.1.5 Vaccine Formulation
    • 2.1.6 Types of Vaccine
      • 2.1.6.1 Classification of Vaccines
      • 2.1.6.2 Live, Attenuated Vaccines
      • 2.1.6.3 Recombinant Live Vaccines
      • 2.1.6.4 Inactivated Vaccines
      • 2.1.6.5 Toxoid Vaccines
      • 2.1.6.6 Subunit Vaccines
      • 2.1.6.7 Conjugate Vaccines
      • 2.1.6.8 Recombinant Subunit Vaccines
      • 2.1.6.9 DNA Vaccines
      • 2.1.6.10 Recombinant Vector Vaccines
  • 2.2 Vaccine Preventable Diseases
    • 2.2.1 Cervical Cancer/Human Papillomavirus (HPV)
    • 2.2.2 Chickenpox and Shingles
    • 2.2.3 Cholera
    • 2.2.4 Diphtheria
    • 2.2.5 Haemophilus influenzae Type b (Hib) Diseases
    • 2.2.6 Hepatitis A
    • 2.2.7 Hepatitis B
    • 2.2.8 Influenza
      • 2.2.8.1 Influenza Prevalence
      • 2.2.8.2 The Influenza Virus
      • 2.2.8.3 Influenza Pandemics and Avian Influenza
      • 2.2.8.4 Influenza Vaccination
    • 2.2.9 Japanese Encephalitis
    • 2.2.10 Measles
    • 2.2.11 Meningococcal Diseases
    • 2.2.12 Mumps
    • 2.2.13 Pertussis
    • 2.2.14 Polio
    • 2.2.15 Rotavirus Diseases
    • 2.2.16 Rubella
    • 2.2.17 Streptococcus Pneumoniae Infections
    • 2.2.18 Tetanus
    • 2.2.19 Tick-Borne Encephalitis
    • 2.2.20 Tuberculosis
    • 2.2.21 Typhoid
    • 2.2.22 Yellow Fever
  • 2.3 Top-Selling Vaccines in 2007
    • 2.3.1 Paediatric Vaccines
      • 2.3.1.1 Prevnar/Prevenar
      • 2.3.1.2 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis)
      • 2.3.1.3 Infanrix/Pediarix
      • 2.3.1.4 Varivax
      • 2.3.1.5 M-M-R II
      • 2.3.1.6 ProQuad
      • 2.3.1.7 Menactra
      • 2.3.1.8 RotaTeq
      • 2.3.1.9 Rotarix
    • 2.3.2 Other/Adult Vaccines
      • 2.3.2.1 Adacel
      • 2.3.2.2 Pneumovax
      • 2.3.2.3 Zostavax
    • 2.3.3 Influenza Vaccines
      • 2.3.3.1 Fluzone/Vaxigrip/Mutagrip
      • 2.3.3.2 Fluarix and FluLaval
      • 2.3.3.3 Fluvirin
    • 2.3.4 Prophylactic Cancer Vaccines
      • 2.3.4.1 Gardasil
      • 2.3.4.2 Cervarix
    • 2.3.5 Hepatitis Vaccines
      • 2.3.5.1 GSK Hepatitis Vaccines
      • 2.3.5.2 Havrix
      • 2.3.5.3 Engerix-B
      • 2.3.5.4 Twinrix/Ambirix
      • 2.3.5.5 Merck & Co./Sanofi Pasteur MSD Hepatitis Vaccines
      • 2.3.5.6 Vaqta/Avaxim
      • 2.3.5.7 Recombivax HB/HBvaxPRO
    • 2.3.6 Therapeutic Vaccines
      • 2.3.6.1 Grazax (ALK-Abell/Menarini)
• 3 The World Vaccine Market
  • 3.1 World Vaccine Market Forecast, 2008-2023
    • 3.1.1 The World Vaccine Market Will Double by 2013
    • 3.1.2 Therapeutic Vaccines Will Become Established
    • 3.1.3 The World Vaccine Market, 2018-2023
  • 3.2 Sales Forecast by Vaccine Class, 2008-2023
    • 3.2.1 The Leading Vaccine Classes in 2007
    • 3.2.2 Paediatric Vaccine Market Share
    • 3.2.3 Other/Adult Vaccines Sales Forecast
    • 3.2.4 Influenza Vaccines Market Growth
    • 3.2.5 Prophylactic Cancer Vaccines Market
    • 3.2.6 Hepatitis Vaccines Market
    • 3.2.7 Rapid Growth for Therapeutic Vaccines
  • 3.3 Leading Vaccine Manufacturers
    • 3.3.1 A Few Major Players Dominate the Vaccine Market
    • 3.3.2 High Entry Barriers to Market
  • 3.4 Sales Forecast for Leading Vaccine Brands, 2008-2013
    • 3.4.1 Leading Paediatric Vaccine Brand Forecasts, 2008-2023
      • 3.4.1.1 Prevnar/Prevenar
      • 3.4.1.2 Polio/Pertussis/Hib Vaccines
      • 3.4.1.3 Infanrix/Pediarix
      • 3.4.1.4 Varivax
      • 3.4.1.5 M-M-R II
      • 3.4.1.6 ProQuad
      • 3.4.1.7 Menactra
      • 3.4.1.8 RotaTeq
      • 3.4.1.9 Rotarix
    • 3.4.2 Leading Other/Adult Vaccine Brand Forecasts, 2008-2023
      • 3.4.2.1 Adacel
      • 3.4.2.2 Pneumovax
      • 3.4.2.3 Zostavax
    • 3.4.3 Leading Influenza Vaccine Brand Forecasts, 2008-2023
    • 3.4.4 Leading Prophylactic Cancer Vaccine Brand Forecasts, 2008-2023
      • 3.4.4.1 Gardasil
      • 3.4.4.2 Cervarix
    • 3.4.5 Leading Hepatitis Vaccine Brand Forecasts, 2008-2023
• 4 SWOT Analysis of the Vaccine Market
  • 4.1 Analysis of the Market
  • 4.2 Key Strengths of the Vaccine Industry
    • 4.2.1 Vaccines Work
    • 4.2.2 New Vaccine Technologies
      • 4.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
      • 4.2.2.2 New Types of Vaccine
      • 4.2.2.3 New Adjuvants for Vaccines
      • 4.2.2.4 New Vaccine Delivery Mechanisms and Formulations
      • 4.2.2.5 Other Developments in Vaccine Technology
    • 4.2.3 New High-Margin Vaccines
    • 4.2.4 Vaccines Will Not Face Significant Generic Competition
    • 4.2.5 Personalised Vaccines
  • 4.3 The Vaccines Industry: Weaknesses
    • 4.3.1 Vaccine Research and Development is Lengthy and Expensive
      • 4.3.1.1 The Vaccine Research and Development Process
      • 4.3.1.2 Vaccine Research and Development and Outsourcing
    • 4.3.2 Vaccine Manufacturing
      • 4.3.2.1 Vaccine Manufacturing has High Costs
      • 4.3.2.2 China, India and Brazil
    • 4.3.3 Consolidation of the Industry
  • 4.4 Opportunities for the Vaccine Industry
    • 4.4.1 Vaccines for Diseases Currently Without a Vaccine
      • 4.4.1.1 The Most Important Non-Vaccine Preventable Diseases
      • 4.4.1.2 Cancer
      • 4.4.1.3 Dengue Fever
      • 4.4.1.4 Epstein-Barr Virus (EBV)
      • 4.4.1.5 Helicobacter Pylori Infections.
      • 4.4.1.6 Hepatitis C
      • 4.4.1.7 Hepatitis E
      • 4.4.1.8 HIV/AIDS
      • 4.4.1.9 Malaria
      • 4.4.1.10 Nosocomial Infections
      • 4.4.1.11 Respiratory Infections
      • 4.4.1.12 Roundworm and Hookworm Infections
      • 4.4.1.13 Sexually-Transmitted Diseases
      • 4.4.1.14 Tobacco
      • 4.4.1.15 West Nile Virus Infections
    • 4.4.2 Improved Vaccines for Partially Vaccine-Preventable Diseases
      • 4.4.2.1 Vaccines Effective Against More Strains
      • 4.4.2.2 Towards a Universal Influenza Vaccine
      • 4.4.2.3 The Need for an Improved Tuberculosis Vaccine
    • 4.4.3 Biodefence
      • 4.4.3.1 The Future for Bioterrorism Vaccines
      • 4.4.3.2 Pandemic-Preparedness
    • 4.4.4 Changing World Demographics
  • 4.5 Key Threats Facing the Vaccine Industry
    • 4.5.1 The Anti-Vaccine Movement
      • 4.5.1.1 Misinformation about Side-Effects of Vaccines
      • 4.5.1.2 MMR Misinformation in the UK
      • 4.5.1.3 Controversy Surrounding Mercury-Containing Vaccines
      • 4.5.1.4 Campaigns Against Cervical Cancer Vaccines
      • 4.5.1.5 Consequences of Anti-Vaccine Campaigns
    • 4.5.2 Vaccines in the Developing World
      • 4.5.2.1 Vaccine Distribution Networks
      • 4.5.2.2 Vaccine Cost in Developing Countries
      • 4.5.2.3 Improving Access to Vaccines in the Developing World
• 5 Vaccine Country Markets
  • 5.1 The Vaccine Market in 2007: Geographical Analysis
    • 5.1.1 The Commercial and Donor Vaccine Markets
    • 5.1.2 Leading Vaccine Country Markets, 2007
    • 5.1.3 Sales Forecast for Leading Vaccine Country Markets, 2008-2023
  • 5.2 Leading Vaccine Country Markets
    • 5.2.1 The US Vaccine Market
      • 5.2.1.1 The US Vaccine Market, 2007
      • 5.2.1.2 The US Vaccine Market, 2008-2023
    • 5.2.2 The European Vaccine Market
      • 5.2.2.1 The German Vaccine Market
      • 5.2.2.2 The French Vaccine Market
      • 5.2.2.3 The UK Vaccine Market
    • 5.2.3 The Japanese Vaccine Market
    • 5.2.4 The Chinese Vaccine Market
      • 5.2.4.1 China is the Largest Vaccine Consumer in the World
      • 5.2.4.2 Chinese Vaccine Manufacturing
      • 5.2.4.3 Chinese Vaccine Research and Development
    • 5.2.5 The Indian Vaccine Market
      • 5.2.5.1 The Indian Vaccine Market is Rapidly Expanding
      • 5.2.5.2 India is an Important Vaccine Exporter
      • 5.2.5.3 Vaccine Research and Development in India
    • 5.2.6 The Donor Vaccine Market
• 6 The Vaccine Pipeline
  • 6.1 The Most Promising Sectors of the Vaccines Pipeline
  • 6.2 Paediatric Vaccines Pipeline
    • 6.2.1 Key Development in Paediatric Vaccines, 2008-2013
    • 6.2.2 Hexaxim
    • 6.2.3 Synflorix
    • 6.2.4 Prevnar 13
    • 6.2.5 Unifive
    • 6.2.6 MenACWY-TT
    • 6.2.7 Menveo/MenACWY-CRM
    • 6.2.8 Hib-MenCY-TT
    • 6.2.9 MenB
    • 6.2.10 Meningitis B Vaccine
    • 6.2.11 ORV 116E
  • 6.3 Other/Adult Vaccines Pipeline
    • 6.3.1 Key Developments in Other/Adult Vaccines, 2008-2013
    • 6.3.2 Japanese Encephalitis Vaccines
      • 6.3.2.1 Ixiaro/IC51
      • 6.3.2.2 ChimeriVax-JE
    • 6.3.3 Adenovirus Vaccines
    • 6.3.4 Simplirix
    • 6.3.5 Flavinum
    • 6.3.6 HIV/AIDS Vaccines
      • 6.3.6.1 ALVAC-HIV/AIDSVAX B/E
      • 6.3.6.2 tgAAC09
      • 6.3.6.3 VRC-HIVADV014-00VP
    • 6.3.7 Biodefence Vaccines
      • 6.3.7.1 Anthrax Vaccine
      • 6.3.7.2 rF1V Plague Vaccine
      • 6.3.7.3 Imvamune
    • 6.3.8 CholeraGarde
    • 6.3.9 Cytomegalovirus Vaccine
    • 6.3.10 Dengue Fever Vaccines
      • 6.3.10.1 ChimeriVax-Dengue
      • 6.3.10.2 Dengue Virus Vaccine
    • 6.3.11 Mosquirix
    • 6.3.12 Nosocomial Infection Vaccines
      • 6.3.12.1 Pseudomonas Aeruginosa Vaccine
      • 6.3.12.2 V 710/Staphylococcus Aureus Vaccine
      • 6.3.12.3 ACAM-CDIFF
      • 6.3.12.4 StaphVAX
    • 6.3.13 143717A/Varicella Zoster Virus Vaccine
    • 6.3.14 Travellers' Diarrhoea Vaccines
      • 6.3.14.1 ACE393/Campylobacter Jejuni Vaccine
      • 6.3.14.2 Travellers' Diarrhoea Vaccine (Escherichia Coli)
    • 6.3.15 GSK M72/Tuberculosis Vaccine
    • 6.3.16 Typhoid Vaccine
    • 6.3.17 ChimeriVax-West Nile
  • 6.4 Influenza Vaccines Pipeline
    • 6.4.1 Key Developments in Influenza Vaccines, 2008-2013
    • 6.4.2 Cell-Based Influenza Vaccines
      • 6.4.2.1 The Switch from Eggs
      • 6.4.2.2 Optaflu
      • 6.4.2.3 Influvac TC
      • 6.4.2.4 FluBlk
      • 6.4.2.5 Vero-Cell Technology
      • 6.4.2.6 Per C6
    • 6.4.3 H5N1 Influenza Vaccines
    • 6.4.4 Novel Delivery Systems for Influenza Vaccines
    • 6.4.5 New Adjuvants for Influenza Vaccines
    • 6.4.6 ACAM-FLU-A
  • 6.5 Hepatitis Vaccines Pipeline
    • 6.5.1 Hepsilav/V270
    • 6.5.2 Hepatitis B Vaccine
    • 6.5.3 V 419/Hepatitis B Vaccine
    • 6.5.4 Hepatitis E Vaccine
  • 6.6 Prophylactic Cancer Vaccines Pipeline
    • 6.6.1 V502/Human Papillomavirus Vaccine
    • 6.6.2 Novel Prophylactic Cancer Vaccines
      • 6.6.2.1 Epstein-Barr Virus Vaccine
      • 6.6.2.2 Helicobacter Pylori Vaccine
  • 6.7 Therapeutic Vaccines Pipeline
    • 6.7.1 Therapeutic Cancer Vaccines
      • 6.7.1.1 Sipuleucel-T/Provenge
      • 6.7.1.2 TroVax
      • 6.7.1.3 MAGE-A3 ASCI
      • 6.7.1.4 Stimuvax
      • 6.7.1.5 OncoVAX
      • 6.7.1.6 MVax
      • 6.7.1.7 CDX-110
      • 6.7.1.8 Reniale
      • 6.7.1.9 Biovaxid
      • 6.7.1.10 Allovectin-7
      • 6.7.1.11 GV1001
    • 6.7.2 Therapeutic Vaccines for Hepatitis
      • 6.7.2.1 Therapeutic Hepatitis B Vaccine
      • 6.7.2.2 IC41/Hepatitis C Vaccine
      • 6.7.2.3 GI-5005/Hepatits C Treatment Vaccine
      • 6.7.2.4 ChronVac-C
    • 6.7.3 Therapeutic Vaccines for HIV Infection
    • 6.7.4 Therapeutic Vaccines for Other Viral Infections
      • 6.7.4.1 TG 4001/R3484 (MVA-HPV-IL2/HPV Vaccine)
      • 6.7.4.2 Cytomegalovirus Therapeutic Vaccine
    • 6.7.5 Therapeutic Addiction Vaccines
      • 6.7.5.1 Addiction Vaccines Will Target Nicotine and Drug Dependence
      • 6.7.5.2 NicVAX
      • 6.7.5.3 NIC002
      • 6.7.5.4 TA-NIC
      • 6.7.5.5 Niccine
      • 6.7.5.6 TA-CD
    • 6.7.6 Therapeutic Allergy Vaccines
      • 6.7.6.1 Pollinex Quattro
      • 6.7.6.2 House Dust Mite Allergy Vaccine
    • 6.7.7 Therapeutic Vaccines for Chronic Disease
• 7 Expert Opinion from Key Opinion-Leaders in the Vaccine Industry
  • 7.1 Dr Michael Watson, Executive Vice President Research and Development,
    • Acambis
    • 7.1.1 The Key Unmet Vaccine Needs in 2008
    • 7.1.2 The Acambis Vaccine Pipeline and the ChimeriVax Platform
    • 7.1.3 A Clostridium Difficile Vaccine
    • 7.1.4 Progress Towards a Universal Influenza Vaccine
    • 7.1.5 Improving Access to Vaccines in Developing Countries
    • 7.1.6 The Future for Biodefence Vaccines
    • 7.1.7 Highlights of the Acambis Pipeline
  • 7.2 Gregory A. Poland, M.D., MACP, FIDSA, Mary Lowell Leary Endowed
    • Professor of Medicine, Infectious Diseases, Molecular Pharmacology and
    • Experimental Therapeutics, Mayo Clinic (US)
    • 7.2.1 Personalised Vaccines
    • 7.2.2 Growth of Therapeutic Cancer Vaccines and Addiction Vaccines
    • 7.2.3 Ignorance and Misconceptions about Vaccines
  • 7.3 Dr Raafat Fahim, President and Chief Executive Officer of Nabi
    • Biopharmaceuticals
    • 7.3.1 Vaccines in the Pipeline for Nicotine Addiction
    • 7.3.2 Vaccines in the Pipeline for Staphylococcus, Including MRSA, Infection
    • 7.3.3 Nabi Biopharmaceuticals are Investigating the Anti-Viral RENS
  • 7.4 Dr Ronald Ellis, Senior Vice President and Chief Technical Officer,
    • NasVax, Israel
    • 7.4.1 The Key Unmet Vaccine Needs in 2008
    • 7.4.2 New Adjuvants for Influenza Vaccines
    • 7.4.3 The Future for Intranasal Vaccines
    • 7.4.4 The Vaccine Technology of the Future
    • 7.4.5 The Future for Therapeutic Vaccines
  • 7.5 Dr Steen S. Klysner, Chief Executive Officer, Nordic Vaccine
    • 7.5.1 Nordic Vaccine's Immune Enhancing Nano-Particle and Skin Patch
      • Vaccine Technology
    • 7.5.2 Vaccine Technology in 2023
    • 7.5.3 Vaccines Will be Developed for New Diseases by 2023
• 8 Conclusions
  • 8.1 The 'Vaccine Boost'
  • 8.2 Vaccines Will Outperform the Overall Pharmaceutical Market During 2008-2023
  • 8.3 Vaccine Growth Drivers
  • 8.4 Emerging Markets for Vaccines
• List of Tables
  • Table 2.1 Vaccine Preventable Disease Statistics
  • Table 2.2 Vaccine Classes
  • Table 2.3 Example Brands for Polio/Pertussis/Hib Vaccines (Sanofi-Aventis*)
  • Table 2.4 Brands in the Infanrix/Pediarix Range of Vaccines
  • Table 3.1 Worldwide Vaccine Market ($bn), 2007-2013
  • Table 3.2 Worldwide Vaccine Market ($bn), 2014-2023
  • Table 3.3 Vaccines Sales ($bn) and Market Share by Vaccine Class, 2007
  • Table 3.4 Vaccines Sales ($bn) by Vaccine Class, 2007-2013
  • Table 3.5 Vaccines Sales ($bn) by Vaccine Class, 2014-2023
  • Table 3.6 Leading Vaccine Manufacturers, 2007
  • Table 3.7 Leading Paediatric Vaccine Sales ($bn), 2007-2013
  • Table 3.8 Leading Other/Adult Vaccine Sales ($bn), 2007-2013
  • Table 3.9 Leading Influenza Vaccine Sales ($bn), 2007-2013
  • Table 3.10 Gardasil Sales ($bn), 2007
  • Table 3.11 Leading Prophylactic Cancer Vaccine Sales ($bn), 2007-2013
  • Table 3.12 Leading Hepatitis Vaccine Sales ($bn), 2007-2013
  • Table 4.1 SWOT Chart for Vaccines Market
  • Table 4.2 Selected Diseases Currently Without a Vaccine
  • Table 4.3 Population Statistics 2007-2023
  • Table 4.4 GDP China, India, US and Japan, 2007-2023
  • Table 5.1 Commercial & Donor Vaccine Market, 2007
  • Table 5.2 Leading Vaccines Country Markets 2007
  • Table 5.3 Vaccines Sales Forecast ($bn) for Leading Country Markets, 2007-2013
  • Table 5.4 Vaccines Sales Forecast ($bn) for Leading Country Markets, 2014-2023
  • Table 6.1 Key Pipeline Paediatric Vaccines
  • Table 6.2 Key Pipeline Other/Adult Vaccines
  • Table 6.3 Key Cell-Culture Influenza Vaccines
  • Table 6.4 Key Pipeline Hepatitis Vaccines
  • Table 6.5 Key Pipeline Prophylactic Cancer Vaccines
  • Table 6.6 Key Pipeline Therapeutic Cancer Vaccines
  • Table 6.7 Key Pipeline Therapeutic Hepatitis Vaccines
  • Table 6.8 Key Pipeline Therapeutic HIV/AIDS Vaccines
  • Table 6.9 Key Pipeline Therapeutic Addiction Vaccines
• List of Figures
  • Figure 3.1 Worldwide Vaccine Market ($bn), 2007-2023
  • Figure 3.2 Market Share by Vaccine Class, 2007
  • Figure 3.3 Paediatric Vaccine Sales ($bn), 2007-2023
  • Figure 3.4 Sales ($bn) by Vaccine Class (Excluding Paediatric Vaccines), 2007-2023
  • Figure 3.5 Vaccine Sales ($bn) and Market Share by Vaccine Class, 2007-2023
  • Figure 3.6 Market Share by Vaccine Class, 2013
  • Figure 3.7 Market Share by Vaccine Class, 2018
  • Figure 3.8 Market Share by Vaccine Class, 2023
  • Figure 3.9 Leading Vaccine Manufacturers, 2007
  • Figure 3.10 Prevnar/Prevenar Sales ($bn), 2007-2013
  • Figure 3.11 Leading Paediatric Combination Vaccine Sales ($bn), 2007-2013
  • Figure 3.12 Varivax, M-M-R II and ProQuad Sales ($bn), 2007-2013
  • Figure 3.13 Menactra Sales ($bn), 2007-2013
  • Figure 3.14 RotaTeq and Rotarix Sales ($bn), 2007-2013
  • Figure 3.15 Adacel Sales ($bn), 2007-2013
  • Figure 3.16 Pneumovax Sales ($bn), 2007-2013
  • Figure 3.17 Zostavax Sales ($bn), 2007-2013
  • Figure 3.18 Leading Influenza Vaccine Sales ($bn), 2007-2013
  • Figure 3.19 Leading Prophylactic Cancer Vaccine Sales ($bn), 2007-2013
  • Figure 3.20 Leading Hepatitis Vaccine Sales ($bn), 2007-2013
  • Figure 4.1 Population of China, India, US and Germany, 2007-2023
  • Figure 4.2 Gross Domestic Product ($tr) for US, Japan, China and India, 2007-2023
  • Figure 5.1 Commercial and Donor Vaccine Market Share, 2007
  • Figure 5.2 Vaccine Market Share by Leading Country, 2007
  • Figure 5.3 Vaccines Sales for Leading Country Markets 2007-2023: Upper Group
  • Figure 5.4 Vaccines Sales for Leading Country Markets 2007-2023: Lower Group
  • Figure 5.5 Vaccine Market Share by Leading Country, 2013
  • Figure 5.6 Vaccine Market Share by Leading Country, 2018
  • Figure 5.7 Vaccine Market Share by Leading Country, 2023
• Companies Listed
  • Acambis
  • Accentia Biopharmaceuticals
  • ACE BioSciences
  • Advisory Committee on Immunization Practices (ACIP) [US]
  • Aeras Global TB Vaccine Foundation
  • ALK-Abell
  • Allergy Therapeutics
  • AnGes MG
  • Antigenics
  • Astellas
  • AstraZeneca
  • AVANT Immunotherapeutics
  • Avax Technologies
  • Barr
  • Bavarian Nordic
  • Baxter
  • Bharat Biotech
  • Bill & Melinda Gates Foundation
  • Biogen Idec
  • Biological E.
  • Biotecnol
  • Celtic Pharma
  • Centers for Disease Control and Prevention (CDC) [US]
  • China National Biotec Group
  • Chiron (acquired by Novartis in 2006)
  • Computer Sciences Corporation (CSC)
  • Crucell
  • CSL
  • Cytos Biotechnology
  • Daiichi Sankyo
  • Dendreon
  • Diamyd Medical
  • Dynavax
  • DynPort Vaccine Company (DVC) [subsidiary of Computer Sciences Corporation (CSC)]
  • Emergent Biosolutions
  • European Medicines Agency (EMEA)
  • Food and Drug Administration (FDA)
  • GAVI Alliance
  • Genelabs
  • Genetic Immunity
  • GenVec
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Green Cross [Korea]
  • Independent Pharmaceutica
  • Inovio Biomedical
  • Intercell
  • International AIDS Vaccine Initiative
  • Intracel
  • Kaketsuken
  • Karolinska Institutet [Sweden]
  • LipoNova
  • Lonza
  • MedImmune (acquired by AstraZeneca in 2007)
  • Menarini
  • Merck & Co.
  • Merck KGaA
  • Mitsubishi Tanabe
  • Nabi Biopharmaceuticals
  • NasVax [Israel]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • Novartis
  • Novavax
  • Oncothyreon
  • Oxford BioMedica
  • Pan American Health Organization (PAHO)
  • Petrovax
  • Pfizer
  • PharmAthene
  • Pharmexa
  • Protein Sciences
  • Ranbaxy
  • Roche
  • Sanofi Pasteur MSD [joint venture between Merck & Co. and Sanofi-Aventis]
  • Sanofi-Aventis
  • Schering-Plough
  • Serum Institute of India
  • Sinovac
  • Solvay
  • Targeted Genetics
  • Therapeutic Goods Administration [Australia]
  • Transgene
  • Tripep
  • UMN Pharma
  • UNICEF (United Nations Children's Fund)
  • University of Queensland [Australia]
  • US Census Bureau
  • Vaccine Research Center (VRC) [part of NIAID, US]
  • Vaccinogen
  • VaxGen
  • Vaxine [Australia]
  • Vical
  • Virax
  • Worldwide Health Organization (WHO)
  • Wyeth
  • Wistar Institute [US]
  • Ludwig Institute of Cancer Research
  • Xenova (acquired by Celtic Pharma in 2005)